New Options for Metastatic Breast Cancer

Debra K. Frye

Suzanne M. Mahon

Frances M. Palmieri

metastases, breast cancer, management
CJON 2009, 13(1), 11-18. DOI: 10.1188/09.CJON.S1.11-18

Patients with advanced breast cancer are living longer and receiving multiple lines of chemotherapy; however, they eventually develop resistance to the agents. Two more agents have been approved for the treatment of breast cancer and will provide additional treatment options for such patients. Ixabepilone represents a new class of cytotoxic chemotherapy called the epothilones. Ixabepilone was approved for use as a single agent for the treatment of metastatic breast cancer resistant to taxanes, anthracyclines, and capecitabine, as well as in combination with capecitabine for disease refractory to taxanes and anthracyclines. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, was approved for first-line treatment of HER2-negative metastatic breast cancer in combination with paclitaxel. Understanding the efficacy, toxicity, and administration of the agents is crucial for oncology nurses to optimally educate and treat patients with advanced breast cancer.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.